RMTG (Regenerative Medical Technology Group) LT-Debt-to-Total-Asset : 0.76 (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Regenerative Medical Technology Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Regenerative Medical Technology Group's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.76.

Regenerative Medical Technology Group's long-term debt to total assets ratio increased from Sep. 2023 (0.13) to Sep. 2024 (0.76). It may suggest that Regenerative Medical Technology Group is progressively becoming more dependent on debt to grow their business.

Regenerative Medical Technology Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Regenerative Medical Technology Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerative Medical Technology Group LT-Debt-to-Total-Asset Chart

Regenerative Medical Technology Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

12.77

25.60

1.27

1.00

0.84

Regenerative Medical Technology Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.84	0.81	0.81	0.76

Regenerative Medical Technology Group LT-Debt-to-Total-Asset Calculation

Regenerative Medical Technology Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	2.425	/	2.879
	=	0.84

Regenerative Medical Technology Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	2.452	/	3.228
	=	0.76

Regenerative Medical Technology Group (OTCPK:RMTG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Regenerative Medical Technology Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Regenerative Medical Technology Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerative Medical Technology Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerative Medical Technology Group Inc (OTCPK:RMTG) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432

Website

https://www.regenmedtechgroup.com

Regenerative Medical Technology Group Inc operates through its subsidiary. Its focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. It believes stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. Patients around the world are seeking a natural regenerative alternative without the potential risks and side effects sometimes associated with conventional pharmaceuticals.

Executives

Benito Novas	10 percent owner	433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
David Eugene Christensen	director, 10 percent owner, officer: President and CEO	433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Pereira Melvin Antonio Loria	director, 10 percent owner, officer: CEO, Chairman	RESIDENCIAL HACIENDA EL GREGAL, #24-1 SANCHEZ, CURRIDABAT, SAN JOSE G2 11803